Access to Healthcare

A day after US company Gilead was granted a patent on hepatitis C medicine, sofosbuvir, patient groups and companies are planning to challenge it. I-MAK and health advocates around the world agree that sofosbuvir does not deserve a patent, and will be launching an appeal to the decision. The order may block a sustainable supply […]

In an editorial in the Hindu, The Centre is reported to be in favour of moving a bill requiring doctors to prescribe generic medicines in place of costly, branded ones. This progressive step, which will reform the way essential medicines are distributed to patients, was recommended by the Planning Commission’s High Level Expert Group on

Government must not place the entire burden of access to healthcare on the pharmaceutical industry alone, Sanofi India has said responding to more medicines being put under price control. Speaking at the company’s annual general meeting held on April 29, the Sanofi India Managing Director Shailesh Ayyangar said any pricing regime must be predictable and

India’s poor will benefit from improved access to essential medicines in India after the government capped the prices of 530 drugs under the price monitoring mechanism, reports The Pharma Letter. Around 47 formulations for cancer, 20 for AIDS/HIV, 53 for cardiovascular diseases and six for diabetes have had their prices reduced recently. As a result